ipilimumab (Yervoy) For the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy.
ipilimumab (Yervoy) Treatment of advanced (unresectable or metastatic) melanoma in adolescents 12 years of age and older.
ipilimumab (Yervoy) Treatment of advanced (unresectable or metastatic) melanoma in adults (first-line use).
nivolumab (Opdivo) In combination with ipilimumab for the treatment of advanced (unresectable or metastatic) melanoma in adults.
nivolumab (Opdivo) In combination with ipilimumab for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma.
nivolumab (Opdivo) In combination with ipilimumab for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma (MPM).
pembrolizumab (Keytruda) As monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults. This submission relates to use in adults previously treated with ipilimumab.
pembrolizumab (Keytruda) As monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults. This submission relates to use in adults previously untreated with ipilimumab.
nivolumab (Opdivo) In combination with ipilimumab for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell programmed death ligand (PD-L1) expression ≥ 1%
nivolumab (Opdivo) nivolumab with ipilimumab (NIVO+IPI) is indicated for the treatment of adults with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-based combination chemotherapy.
nivolumab (Opdivo) In combination with ipilimumab and 2 cycles of platinum-based doublet chemotherapy (PDC) is indicated for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumours have no sensitising epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) translocations.
nivolumab (Opdivo) In combination with ipilimumab (YERVOY®) (NIVO + IPI) is indicated for the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability high (MSI-H) colorectal cancer (CRC) in the following settings: first-line treatment of unresectable or metastatic CRC.
November 2015 decisions news release The Scottish Medicines Consortium (SMC) has announced today that four new medicines have been accepted for routine use by NHSScotland.
November 2016 decisions news release The Scottish Medicines Consortium (SMC) has today published advice accepting five new medicines for routine use in NHSScotland.
November 2014 decisions news release This month’s advice from the Scottish Medicines Consortium (SMC) will benefit patients with a range of conditions across Scotland. SMC is the body that advises NHSScotland on the clinical and cost-effectiveness of all newly licensed medicines.
